Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Regeneron Pharmaceuticals Ins has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. ROBINSON, HOPE A is the busiest examiner, managing 1 pending office action. The current prosecution activity for this portfolio is limited to 1 pending office action, indicating a very focused immediate workload.
With 1 distinct examiner and 1 distinct art unit involved, the company's immediate efforts are focused on a single point of contact. This streamlined structure simplifies the administrative oversight required for the company's biotechnology and pharmaceutical filings. Practitioners can focus their strategy entirely on the preferences of ROBINSON, HOPE A and the standards of the assigned art unit. Because there is only 1 pending office action, its resolution is the primary factor in the company's current patent progress. This concentrated approach allows for a highly specialized interaction with the patent office, ensuring that all resources are directed toward the single pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18540975 | SYSTEMS AND METHODS FOR PREPARING A POLYPEPTIDE FROM A MIXTURE | ROBINSON, HOPE A | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18540975 | SYSTEMS AND METHODS FOR PREPARING A POLYPEPTIDE FROM A MIXTURE | ROBINSON, HOPE A | 1652 | §103 | Final Rejection | — | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegeneron Pharmaceuticals Ins has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hope A Robinson has the most, with 1 of Regeneron Pharmaceuticals Ins's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
